The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig
... cross action. Round handle. Divides nucleus for p...ithout grooving. Nuclei of any hardness can be pre...er. Phaco of pre-chopped nuclear fragments is rapi...ving is diminished. Shortened ultra sound time and...
Karate chopper, spear shaped for ease of insertion into the nucleus.
Phaco chopper & iris retractor 2 mm cutting edge.
Medicine Products:(Date:5/15/2008)..., 2008 -- The Society for Cardiovascular Angiogra...it will hold its 2009 Annual Scientific Sessions M...cused, collegial interventional cardiology meeting...ng time beginning in 2010. , The 2009 SCAI Annua...tional cardiology meeting of the spring for practi...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT)...ounced that, on May,12, 2008, it had received a NA...ompany,s requests for continued listing on The NAS...ed that the Company did not provide a,definitive p...mpliance with,the continued listing requirements o...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq... committed to,discovering, developing and commerci...orted unaudited financial results for the second f...orted a net loss attributable,to common stockholde...quarter ended March 31, 2008, as compared to a net...
(Date:5/15/2008)...wswire-USNewswire/ -- The American Public,Health A...r overwhelmingly,passing the 2008 farm bill and ur...egislation when it arrives on his desk., Along wi... broad,support among organizations representing th...utrition interests., "While this legislation is n...
Breaking Medicine News(10 mins):Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8... found anti-clotting drug called bivalirudin (Angi...rapy for patients with acute coronary syndromes su...s to be less risky for patients suffering from acu... the ‘Acute Catheterization and Urgent Interventio...
...e of bird flu had been discovered in a Farm in Sou...ing authorities to cull thousands more, South Kore...While speaking in a news conference, Kim Chang-sub...rantine department said: 'This case appears quite ...
...d safety officials have banned the sale of turbot ...ents in fish //at several of Beijing’s fish market...introduced by Cao Jilin from Europe in 1992. Due ...h are fed on medicinal supplements, which sometime...
...stitute for Health Information has grouped the fiv...real and Halifax into neighbourhoods, based on fiv...ants, people living alone and lone-parent families...d housing conditions and other social issues to kn...
Other Medicine News:Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Health Of Residents Is Affected by Various Factors 2(Date:5/15/2008)...Showed Acceptable Tolerability Profile, ... WOODCLIFF LAKE, N.J., May 15 /- The ...sylate (E7389) demonstrated activity in a,heavily ...ed or metastatic,breast cancer, according to resul...study also suggests that eribulin mesylate has a m...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... /- Ergonex Pharma today,announced th...(FDA) has,granted orphan drug designation to Tergu...tension (PAH). Terguride is currently being evalua..., "The FDA,s grant of orphan drug designation to ...evelopment program by offering regulatory,clinica...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 1Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 4Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 1Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 2ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 1ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 2Vioxx Settlement Announced 6028 1..., 2007 - New data show the,investigational drug te...ted with Huntington,s disease (HD) up to 80 weeks ...ment in a 13-week trial.,These data suggest that t...educed chorea burden in long-term use., "These fin...nazine as maintenance therapy for U.S. patients wh...
...RE)--May 4, 2007 - New data from a,randomized, dou...ONE(R) (glatiramer acetate injection) along with t...um (Gd)-enhancing lesions,of the brain by 63 perce...tting multiple sclerosis (RRMS), as measured by,ma...receiving,COPAXONE(R) alone. Additionally, the nin...
Other Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5